Search Back New search Go to resultsDiseaseMain groupSupportive Therapy, ToxicityProtocol groupComplicationsDiseaseGraft-versus-Host Disease, acuteSubgroupICD10T86.01+T86.02+MeSHGraft vs Host DiseaseSequenceChemotherapyChemo-substanceRuxolitinibChemo-substanceRuxolitinibChemo-substanceRuxolitinibChemo-substanceRuxolitinibNo. Substances1 RadiotherapySupportive therapySupportive substanceSupportive substanceSupportive substanceSupportive substanceNo. SubstancesProtocol classificationTherapy classificationcurrent standardIntensityStandard doseTherapy indicationRefractory diseaseTherapy phaseTherapy intentiondisease controlRisksAnemia Hb below 8g/dlCMV Infection (asympt. + sympt.)DiarrheaEdemaEmetogenicity (MASCC/ESMO)HypertensionHypoalbuminemiaHypocalcemiaHypokalemiaHypomagnesemiaHypophosphatemiaInfectionsNeutropeniaPneumoniaSepsisThrombocytopenia below 50 000/µl only studiesPublicationAuthorZeiser RDiseaseAkute Graft-versus-Host-Erkrankung Grad II-IV, steroidrefraktärOriginUniversity Medical Center Freiburg, Freiburg, Germany, REACH2 TrialProtocols in Revision 1 protocol foundProtocols under revision.Ruxolitinib 10, Graft-versus-Host Disease, acute (PID2108 V1.0)
